2017 Press Releases

Webcast ImageWebcast
Aeglea BioTherapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference (Replay)
12/14/17 at 8:30 a.m. ET
Aeglea BioTherapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
Thursday, December 14, 2017 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015
DateTitle 
12/07/17Aeglea BioTherapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
Company to Webcast Presentation on Thursday, December 14 at 8:30 a.m. ET AUSTIN, Texas, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to the discovery and development of engineered human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it will provide a corporate update at the upcoming BMO Capital Markets Prescription for Success Healthcare Conference in New York on Thursday, December... 
11/29/17Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102)
Clinical Agreement Reached with FDA to Enable Pediatric Dosing AUSTIN, Texas, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to the discovery and development of engineered human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced dosing of the first pediatric patient in its ongoing Phase 1/2 clinical trial in patients with Arginase 1 Deficiency and provided a regulatory update on its pegzilarg... 
11/07/17Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
AUSTIN, Texas, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today provided a corporate update and reported financial results for the third quarter ended September 30, 2017. “I am very pleased with the forward momentum and progress of the team at Aeglea over the last few months. Initiation of repeat dosing ... 
11/02/17Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting
AUSTIN, Texas, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it will deliver a poster presentation about preclinical findings from an evaluation of Aeglea’s AEB1102 (pegzilarginase) combined with immunomodulators at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting taking ... 
10/16/17Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea’s AEB1102 (pegzilarginase) with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Small Cell Lung Cancer
AUSTIN, Texas, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced it has entered into a clinical collaboration agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of Aeglea’s AEB1102 (pegzilarginase) with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembroli... 
09/06/17Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency
Topline data is expected in second half of 2018 AUSTIN, Texas, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it has dosed two adults in the repeat dose part of its Phase 1/2 clinical trial of AEB1102 (pegzilarginase) for the treatment of patients with Arginase 1 Deficiency. Initial re... 
08/31/17Aeglea BioTherapeutics to Present at the 2017 Wells Fargo Healthcare Conference
AUSTIN, Texas, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that management will be presenting at the 2017 Wells Fargo Healthcare Conference in Boston on Wednesday, September 6 at 8:30 a.m. ET. To access the live and archived webcast of the presentation, please visit the Investor Relations ... 
08/09/17Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results
AUSTIN, Texas, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today provided a corporate update and reported financial results for the second quarter ended June 30, 2017. “With our newly expanded and strengthened management team, we are well positioned to advance our clinical development strategy for AEB1102... 
07/20/17Aeglea BioTherapeutics Announces Leadership Change
Anthony Quinn, M.B Ch.B, Ph.D., Aeglea board member, former head of R&D at Synageva BioPharma, named interim CEO AUSTIN, Texas, July 20, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that David G. Lowe, Ph.D., resigned as the company’s president, chief executive officer and director, effective imme... 
07/10/17Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer
AUSTIN, Texas, July 10, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it has appointed James Wooldridge, M.D. to the position of chief medical officer. Dr. Wooldridge joins Aeglea from Eli Lilly & Company, where he served as chief scientific officer for immuno-oncology clinical development. ... 
06/06/17Aeglea BioTherapeutics Prices Public Offering of Common Stock
AUSTIN, Texas, June 06, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced the pricing of its underwritten public offering of 3,000,000 shares of common stock at a public offering price of $4.10 per share, with expected gross proceeds to Aeglea of $12.3 million. The offering is expected to close on June 9, 2... 
06/05/17Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
AUSTIN, Texas, June 05, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it has commenced an underwritten public offering of common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms ... 
05/23/17Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
--Announces three single agent expansion arms for AEB1102 solid tumor trials-- --Provides update on AEB1102 program in Arginase 1 Deficiency-- --Company names Aaron Schuchart as chief business officer-- AUSTIN, Texas, May 23, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today provided an AEB1102 program and corpo... 
05/16/17Aeglea BioTherapeutics to Present at the UBS 2017 Global Healthcare Conference
AUSTIN, Texas, May 16, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that management will be presenting at the UBS 2017 Global Healthcare Conference in New York on Tuesday, May 23 at 1:00 p.m. ET. To access the live and archived webcast of the presentation, please visit the Investor Relations section... 
05/09/17Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results
AUSTIN, Texas, May 09, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today provided a corporate update and reported financial results for the first quarter ended March 31, 2017. “AEB1102 remains the primary focus of our clinical and preclinical work across rare genetic diseases and cancer,” said David G. Lowe, Ph.D.... 
03/29/17Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting
AUSTIN, Texas, March 29, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it will deliver a poster presentation at the 2017 American Association for Cancer Research (AACR) Annual Meeting taking place April 1 – 5 in Washington, DC. Full abstracts are available online at www.aacr.org. Details of the ... 
03/28/17Aeglea BioTherapeutics to Present at the 16th Annual Needham Healthcare Conference
AUSTIN, Texas, March 28, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it will present a corporate update at the 16th Annual Needham Healthcare Conference in New York on Tuesday, April 4 at 2:20 p.m. ET.   To access the live and archived webcast of the presentation, please visit the Investor Rel... 
03/23/17Aeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
-- Topline Results Presented Today of Phase 1 Open-Label Study of AEB1102 Enzyme Replacement Therapy in Adult Patients with Arginase I Deficiency -- -- Conference Call Today at 4:30 p.m. ET to Provide Corporate Update and Review Arginase I Deficiency Clinical Results -- AUSTIN, Texas, March 23, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genet... 
03/23/17Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics Meeting
AUSTIN, Texas, March 23, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancers, today announced topline data from a Phase 1 open-label study evaluating the safety and tolerability of its lead product candidate, AEB1102, for patients with Arginase I deficiency. The poster, entitled “Initial Results of a Phase I Open-Label Study... 
03/17/17Aeglea BioTherapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results on Thursday, March 23
Company to host conference call and webcast to provide business update and review topline Phase 1 Arginase I deficiency clinical results AUSTIN, Texas, March 17, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it will report its financial results for the quarter and year ended December 31, 2016 on T... 
02/28/17Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at Keystone Symposia Conference on Tumor Metabolism
AUSTIN, Texas, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it will present at the 2017 Keystone Symposia Conference on Tumor Metabolism: Mechanisms and Targets, taking place March 5 – 9 in Whistler, British Columbia. Details of the presentation, which will be delivered both orally and a... 
02/16/17Aeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors
AUSTIN, Texas, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced the appointment of Suzanne L. Bruhn, Ph.D. to its Board of Directors. Dr. Bruhn previously served as chief executive officer, president and director at Promedior, Inc., a clinical-stage biotechnology company, from 2012 to 2015. “Su... 
01/17/17Aeglea BioTherapeutics to Present New Data at 2017 ACMG Annual Clinical Genetics Meeting
Presentation includes positive initial data from Phase 1 clinical study of AEB1102 for the treatment of Arginase I deficiency AUSTIN, Texas, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it will present new clinical and research data in two presentations at the 2017 American College of Me...